Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Trimipramine
Drug ID BADD_D02294
Description Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties.
Indications and Usage For the treatment of depression and depression accompanied by anxiety, agitation or sleep disturbance
Marketing Status approved
ATC Code N06AA06
DrugBank ID DB00726
KEGG ID D00394
MeSH ID D014299
PubChem ID 5584
TTD Drug ID D00HZV
NDC Product Code Not Available
UNII 6S082C9NDT
Synonyms Trimipramine | Trimeprimine | 10,11 Dihydro-N,N,beta-trimethyl-5H-dibenz(b,f)azepine-5-propanamine | Trimipramine, (-)-Isomer | Herphonal | Trimineurin | Novo-Tripramine | Novo Tripramine | NovoTripramine | Nu-Trimipramine | Nu Trimipramine | NuTrimipramine | Rhotrimine | Stangyl | Surmontil | Surmontil Maleate | Trimidura | Trimineurin Maleate | Trimipramin AZU | Trimipramin Beta | Beta, Trimipramin | Trimipramin Stada | Trimipramin-Neurazpharm | Trimipramin Neurazpharm | TrimipraminNeurazpharm | Trimipramine Maleate | Trimipramine Maleate (1:1) | Trimipramine Maleate (1:1), (+)-Isomer | Trimipramine Maleate (1:1), (+-)-Isomer | Trimipramine Maleate (1:1), (-)-Isomer | Trimipramine Mesylate | Trimipramine Monohydrochloride | Trimipramine, (+-)-Isomer | Eldoral | Apo-Trimip | Apo Trimip | ApoTrimip
Chemical Information
Molecular Formula C20H26N2
CAS Registry Number 3564-75-8
SMILES CC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Eosinophilia01.02.04.001--
Extrapyramidal disorder17.01.02.007--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Galactorrhoea21.05.02.002; 05.03.04.002--Not Available
Gynaecomastia21.05.04.003; 05.05.02.003--
Hallucination19.10.04.003--
Headache17.14.01.001--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkinesia17.01.02.008--Not Available
Hypertension24.08.02.001--
Hypoaesthesia17.02.06.023; 23.03.03.081--Not Available
Hypomania19.16.02.001--Not Available
Hypotension24.06.03.002--
Ileus paralytic07.02.05.001--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Jaundice01.06.04.004; 23.03.03.030; 09.01.01.004--Not Available
Libido decreased21.03.02.005; 19.08.03.001--
Lymphadenitis01.09.01.001--Not Available
Malaise08.01.01.003--
Muscular weakness17.05.03.005; 15.05.06.001--
Mydriasis17.02.11.003; 06.05.03.004--Not Available
Myocardial infarction24.04.04.009; 02.02.02.007--
Nausea07.01.07.001--
Neuropathy peripheral17.09.03.003--Not Available
Nightmare19.02.03.003--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Palpitations02.11.04.012--
Pancytopenia01.03.03.003--Not Available
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene